- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC Sets 4th Annual Patient-Centered Diabetes Care Conference; Lonny Reisman, MD, to Give Keynote
Sessions on obesity and the role of technology in disease management will be part of the annual gathering of stakeholders, presented by The American Journal of Managed Care, April 7-8, 2016, at the Teaneck Marriott at Glenpointe in Teaneck, New Jersey.
FOR IMMEDIATE RELEASEDecember 20, 2015
PLAINSBORO, N.J.—The American Journal of Managed Care (AJMC) will bring together stakeholders from across the healthcare spectrum for the fourth annual meeting of Patient-Centered Diabetes Care, which will take place April 7-8, 2016, outside New York City at the Marriott at Glenpointe in Teaneck, New Jersey. To register or find more information, click here.
Lonny Reisman, MD, the founder and chief executive officer of HealthReveal, will offer the keynote address, and Robert A. Gabbay, MD, PhD, FACP, chief medical officer at Joslin Diabetes Center and editor-in-chief of Evidence-Based Diabetes Management, a publication of AJMC, will serve as meeting chair.
Dr. Reisman, who was formerly the chief medical officer at Aetna, recently authored a commentary, which was part of the AJMC 20th anniversary guest commentary series in, titled, “Clinical Efficacy: A Cost-Containment Weapon for the 21st Century.”
The unique format of Patient-Centered Diabetes Care brings together providers, payers, and leaders from the world of policy, pharmaceutical manufacturing, academia, quality measurement, patient education, and advocacy. Over two days, healthcare leaders who might not typically cross paths are asked to share ideas on care delivery, reimbursement, and other “real-world” issues in diabetes care. The hope is that the conversations continue after the meeting ends.
“A meeting like Patient-Centered Diabetes Care has never been more important,” said Brian Haug, president of AJMC Managed Markets Network. “Reimbursement will be more focused on alternate payment models in 2016, and those who fail to engage patients in their own care will suffer the consequences. Diabetes management is ground zero for the new reality. This meeting provides a critical forum to share strategies to help patients and providers navigate the new landscape.”
The 2016 meeting will feature new sessions on obesity and the use of technology in health management, Haug said.
About the Journals and AJMC.com
The American Journal of Managed Care celebrates its 20th year in 2015 as the leading peer-reviewed journal dedicated to issues in managed care. AJMC.com distributes healthcare news to leading stakeholders across a variety of platforms. Other titles in the franchise include The American Journal of Pharmacy Benefits, which provides pharmacy and formulary decision-makers with information to improve the efficiency and health outcomes in managing pharmaceutical care, and The American Journal of Accountable Care, which publishes research and commentary on innovative healthcare delivery models facilitated by the 2010 Affordable Care Act. AJMC’s Evidence-Based series brings together stakeholder views from payers, providers, policymakers and pharmaceutical leaders in oncology and diabetes management. To order reprints of articles appearing in AJMC publications, please call (609) 716-7777, x 131.
CONTACT: Nicole Beagin (609) 716-7777 x 131
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More
